This is a working overview of actin binding, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-08-17. Anything still debated is marked as such rather than presented as settled.
Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | ≈889 Da for the 7-residue fragment | Full-length thymosin beta-4 is ≈4.9 kDa; catalogs differ |
| Appearance | White to off-white powder | Hygroscopic; weight shifts with residual moisture |
| Solubility class | Freely soluble in water | Also dissolves in aqueous buffers; poorly soluble in nonpolar solvents |
| Typical storage temperature | −20 °C, desiccated, protected from light | Once rehydrated, short-term holding at 2-8 °C |
| Typical analytical method | Reversed-phase HPLC with mass spectrometry | Purity by UV absorbance; identity by ESI-MS or MALDI-TOF |
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Identity and purity are assessed with a small set of standard techniques. Reverse-phase high-performance liquid chromatography gives a purity estimate from peak area, usually recorded at 214 or 220 nanometers, where the peptide bond absorbs. Mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidized species. Amino acid analysis or tandem mass spectrometry sequencing can verify the sequence itself. Additional quality attributes include water content, residual trifluoroacetic acid carried over from purification, and endotoxin where the material is intended for biological work.
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
Research peptides are typically supplied as a white to off-white lyophilised powder in a sealed vial. The dry solid is more stable than a solution and is normally kept refrigerated or frozen until use. Dissolution is usually done in water, phosphate-buffered saline or a similar aqueous medium, depending on the assay. Because the material is hygroscopic and easily contaminated, opening vials in a low-humidity environment and recording the lot number before use are standard laboratory practices.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
== Lobbying == The company engages in lobbying in the United States. It also lobbies the Government of Ontario and House of Commons of Canada through Rubicon Strategy, a firm owned by Progressive Conservative Party of Ontario campaign manager Kory Teneycke. Pfizer lobbied various officials in the Government of British Columbia between April and November 2012, including then-premier Christy Clark, future premier John Horgan, future health minister Adrian Dix, and future deputy premier, minister of public safety and solicitor general Mike Farnworth. Notable lobbying organizations or think tanks to which the company has contributed include BIOTECanada, Bipartisan Policy Center, The Business Council, Business Council for the United Nations, Center on Budget and Policy Priorities, European Federation of Pharmaceutical Industries and Associations, Foundation for the National Institutes of Health, Global Health Council, Innovative Medicines Canada, International Federation of Pharmaceutical Manufacturers & Associations, National Health Council, Pharmaceutical Advertising Advisory Board, Pharmaceutical Research and Manufacturers of America, Reagan-Udall Foundation, U.S. Global Leadership Coalition, and World Economic Forum.
== Essays == "The Philosophy of Dress" First published in The New-York Tribune (1885), published for the first time in book form in Oscar Wilde On Dress (2013). "The Decay of Lying" First published in Nineteenth Century (1889), republished in Intentions (1891). "Pen, Pencil and Poison" First published in the Fortnightly Review (1889), republished in Intentions (1891). "The Soul of Man under Socialism" First published in the Fortnightly Review (1891), republished in The Soul of Man (1895), privately printed. ("The Soul of Man Under Socialism" on Wikisource) Intentions (1891) Wilde revised his dialogues on aesthetic subjects for publication in this volume, which comprises: "The Critic as Artist" "The Decay of Lying" "The Truth of Masks" "Phrases and Philosophies for the Use of the Young" first published in the Oxford student magazine The Chameleon, December 1894) ("Phrases and Philosophies for the Use of the Young" on Wikisource) "A Few Maxims For The Instruction Of The Over-Educated" First published, anonymously, in the 1894 November 17 issue of Saturday Review.
By the spring of 1917, the War was dragging on towards its fourth year, and Zita's brother Prince Sixtus of Bourbon-Parma, a serving officer in the Belgian Army, was a main mover behind a plan for Austria-Hungary to make a separate peace with France. Charles initiated contact with Sixtus through contacts in neutral Switzerland, and Zita wrote a letter inviting him to Vienna. Zita's mother, Maria Antonia, delivered the letter in person. Sixtus arrived with conditions for talks which had been agreed with the French – the restoration to France of Alsace-Lorraine (annexed by Germany after the Franco-Prussian War in 1870); restoration of the independence of Belgium; independence for the kingdom of Serbia; and the handover of Constantinople to Russia. Charles agreed, in principle, to the first three points and wrote a letter to Sixtus dated 25 March 1917 which sent "the secret and unofficial message" to the President of France that "I will use all means and all my personal influence". This attempt at dynastic diplomacy eventually foundered. Germany refused to negotiate over Alsace-Lorraine, and, seeing a Russian collapse on the horizon, was loath to give up the war. Sixtus continued his efforts, even meeting David Lloyd George in London about Italy's territorial demands on Austria in the 1915 Treaty of London, but the Prime Minister could not persuade his generals that Britain should make peace with Austria. Zita managed a personal achievement during this time by stopping the German plans to send airplanes to bomb the home of the King and Queen of Belgium on their name days.
Developmental birth defects associated with elevated AFP Omphalocele Gastroschisis Neural tube defects: elevated α-fetoprotein in amniotic fluid and maternal serum Tumors associated with elevated AFP Hepatocellular carcinoma Metastatic disease affecting the liver Nonseminomatous germ cell tumors Yolk sac tumor Other conditions associated with elevated AFP Ataxia telangiectasia: elevated AFP is used as one factor in diagnosis A peptide derived from AFP that is referred to as AFPep is claimed to possess anti-cancer properties. In the treatment of testicular cancer it is paramount to differentiate seminomatous and nonseminomatous tumors. This is typically done pathologically after removal of the testicle and confirmed by tumor markers. However, if the pathology is pure seminoma but the AFP is elevated, the tumor is treated as a nonseminomatous tumor because it contains yolk sac (nonseminomatous) components.
More divergent allele pairs enable presentation of a broader and less redundant repertoire of peptides, thereby potentially enhancing immune recognition. This concept, sometimes referred to as MHC or HLA evolutionary divergence, extends classical models of MHC diversity and heterozygote advantage by treating allelic variation as a continuum rather than a binary state. MHC diversity has also been suggested as a possible indicator for conservation, because large, stable populations tend to display greater MHC diversity than smaller, isolated populations. Small, fragmented populations that have experienced a population bottleneck typically have lower MHC diversity. For example, relatively low MHC diversity has been observed in the cheetah (Acinonyx jubatus), Eurasian beaver (Castor fiber), and giant panda (Ailuropoda melanoleuca). In 2007 low MHC diversity was attributed a role in disease susceptibility in the Tasmanian devil (Sarcophilus harrisii), native to the isolated island of Tasmania, such that an antigen of a transmissible tumor, involved in devil facial tumour disease, appears to be recognized as a self antigen. To offset inbreeding, efforts to sustain genetic diversity in populations of endangered species and of captive animals have been suggested. In ray-finned fish like rainbow trout, allelic polymorphism in MHC class II is reminiscent of that in mammals and predominantly maps to the peptide binding groove.
Sources: en.wikipedia.org
He therefore suggested enlarged sexual signals helped maintain the bond between a mated male and female even though they performed different duties and therefore were separated for lengths of time. A 2001 study proposed that the rounded shape of a woman's breast evolved to prevent the sucking infant offspring from suffocating while feeding at the teat; that is, because of the human infant's small jaw, which did not project from the face to reach the nipple, they might block the nostrils against the mother's breast if it were of a flatter form (compare with the common chimpanzee). Hypothetically, as the human jaw receded into the face, the woman's body compensated with round breasts. Ashley Montagu (1965) proposed that breasts came about as an adaptation for infant feeding for a different reason, as early human ancestors adopted bipedalism and the loss of body hair. Human upright stance meant infants must be carried at the hip or shoulder instead of on the back as in the apes. This gives the infant less opportunity to find the nipple or the purchase to cling on to the mother's body hair. The mobility of the nipple on a large breast in most human females gives the infant more ability to find it, grasp it and feed. Other suggestions include simply that permanent breasts attracted mates, that "pendulous" breasts gave infants something to cling to, or that permanent breasts shared the function of a camel's hump, to store fat as an energy reserve.
They described MDMA as inducing "an easily controlled altered state of consciousness with emotional and sensual overtones" comparable "to marijuana, to psilocybin devoid of the hallucinatory component, or to low levels of MDA". While not finding his own experiences with MDMA particularly powerful, Shulgin was impressed with the drug's disinhibiting effects and thought it could be useful in therapy. Believing MDMA allowed users to strip away habits and perceive the world clearly, Shulgin called the drug window. Shulgin occasionally used MDMA for relaxation, referring to it as "my low-calorie martini", and gave the drug to friends, researchers, and others who he thought could benefit from it. One such person was Leo Zeff, a psychotherapist who had been known to use psychedelic substances in his practice. When he tried the drug in 1977, Zeff was impressed with the effects of MDMA and came out of his semi-retirement to promote its use in therapy. Over the following years, Zeff traveled around the United States and occasionally to Europe, eventually training an estimated four thousand psychotherapists in the therapeutic use of MDMA. Zeff named the drug Adam, believing it put users in a state of primordial innocence. Psychotherapists who used MDMA believed the drug eliminated the typical fear response and increased communication. Sessions were usually held in the home of the patient or the therapist. The role of the therapist was minimized in favor of patient self-discovery accompanied by MDMA induced feelings of empathy.
Dredd is a 2012 science fiction action film directed by Pete Travis and written and produced by Alex Garland. It is based on the 2000 AD comic strip Judge Dredd and its eponymous character created by John Wagner and Carlos Ezquerra. Karl Urban stars as Judge Dredd, a law enforcer given the power of judge, jury, and executioner in a vast, dystopic metropolis called Mega-City One that lies in a post-apocalyptic wasteland. Dredd and his rookie partner, Judge Anderson (Olivia Thirlby), are forced to bring order to a 200-storey high-rise block of apartments and deal with its resident drug lord, Ma-Ma (Lena Headey). Garland began writing the script in 2006, although the development of a new Judge Dredd film adaptation, unrelated to the 1995 film Judge Dredd, was not announced until December 2008. Produced by British studio DNA Films, Dredd began principal photography, using 3D cameras throughout, in November 2010. Filming took place on practical sets and locations in Cape Town and Johannesburg. Dredd was released on 7 September 2012 in the United Kingdom and on 21 September worldwide. Critics were generally positive about the film's visual effects, casting and action sequences, while criticism focused on excessive violence as well as a perceived lack of the satirical elements that are found in the source comic. Despite the positive critical response, the film earned just over $41 million at the box office on an estimated budget of $30–45 million.
=== Metabolic panel === A Metabolic Panel (MP) is a routine group of blood tests commonly used for health screenings, disease detection, and monitoring vital signs of hospitalized patients with specific medical conditions. MP panel analyzes common analytes in the blood to assess the functions of the kidneys and liver, as well as electrolyte and acid-base balances. There are two types of MPs - Basic Metabolic Panel (BMP) or Comprehensive Metabolic Panel (CMP).
Sources: en.wikipedia.org
==== Metabolism ==== Atomoxetine is primarily metabolized via oxidative metabolism. The three major metabolic pathways include aromatic ring hydroxylation mainly by CYP2D6 but also other cytochrome P450 enzymes into 4-hydroxyatomoxetine, benzylic hydroxylation by an unspecified enzyme into 2-hydroxymethylatomoxetine, and N-demethylation by CYP2C19 into N-desmethylatomoxetine. In addition, N-desmethylatomoxetine undergoes hydroxylation by CYP2D6 into N-desmethyl-4-hydroxyatomoxetine. The hydroxylated metabolites of atomoxetine undergo glucuronidation via UDP-glucuronyltransferase (UGT) enzymes to form glucuronide conjugates. As previously described, first-pass metabolism of atomoxetine is substantially greater, bioavailability is lower, peak levels and total exposure are much greater, and elimination half-life is much longer in CYP2D6 poor metabolizers than in extensive metabolizers. The overall metabolism of atomoxetine is similar regardless of CYP2D6 status. In addition, 4-hydroxyatomoxetine remains the major metabolite of atomoxetine independently of CYP2D6 status. But the quantitative amounts of formed atomoxetine metabolites and their rates of formation are substantially different depending on CYP2D6 status. Studies with radiolabeled atomoxetine have shown that peak levels of radioactivity are essentially the same between CYP2D6 extensive metabolizers and CYP2D6 poor metabolizers. However, total exposure of radioactivity was larger and elimination half-life of radioactivity was longer (62 hours vs.
== Problems faced in drug delivery == Other problems persist besides just simply getting through the blood–brain barrier. The first of these is that a lot of times, even if a compound transverses the barrier, it does not do it in a way that the drug is in a therapeutically relevant concentration. This can have many causes, the most simple being that the way the drug was produced only allows a small amount to pass through the barrier. Another cause of this would be the binding to other proteins in the body rendering the drug ineffective to either be therapeutically active or able to pass through the barrier with the adhered protein. Another problem that must be accounted for is the presence of enzymes in the brain tissue that could render the drug inactive. The drug may be able to pass through the membrane fine, but will be deconstructed once it is inside the brain tissue rendering it useless. All of these are problems that must be addressed and accounted for in trying to deliver effective drug solutions to the brain tissue.
Even if submerging them in a desiccant were more effective than leaving them to dry in open air, common desiccants such as silica gel or cat litter are better than rice. Mobile phones do not create considerable electromagnetic interference when used in hospitals. The Apple logo was not inspired by Alan Turing or his death by cyanide-laced apple. Although Turing was found dead with a half-eaten apple near his bed in 1954 and was a key figure in computing history, Apple's logo designer Rob Janoff has repeatedly denied any connection.
Pelvic floor exercise (PFE), also known as Kegel exercises, may improve the tone and function of the pelvic floor muscles, which is of particular benefit for women (and less commonly men) who experience stress urinary incontinence. However, compliance with PFE programs often is poor, PFE generally is ineffective for urinary incontinence unless performed with biofeedback and trained supervision, and in severe cases it may have no benefit. Pelvic floor muscle tone may be estimated using a perineometer, which measures the pressure within the vagina. Medication may also be used to improve continence. In severe cases, surgery may be used to repair or even to reconstruct the pelvic floor. One surgery which interrupts pelvic floor musculature in males is a radical prostatectomy. With the removal of the prostate, many males experience urinary incontinence post operation; pelvic floor exercises may be used to counteract this pre and post operation. Pre-operative pelvic floor exercising significantly decreases the prevalence of urinary incontinence post radical prostatectomy. Prostatitis and prostatectomies are two contributors to erectile dysfunction; following a radical prostatectomy studies show that erectile dysfunction is improved by pelvic floor muscle training under the supervision of physical therapists certified in pelvic floor rehabilitation. Perineology or pelviperineology is a specialty dealing with the functional troubles of the three axes (urological, gynecological and coloproctological) of the pelvic floor.
== External links == Online Physics Tutorial for MRI and MRS https://aclarion.com/ NOCISCAN (aclarion) – The first, evidence-supported, SaaS platform to leverage MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine.
Sources: en.wikipedia.org
Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.
The name is a commercial label rather than a systematic chemical designation, so different vendors and papers attach it to different sequences. Some treat it as a fragment and others as the whole protein. Comparing two reports therefore requires checking what each one actually analyzed.
Typically it reflects the relative area of the main peak in a reversed-phase chromatogram at a given wavelength. It does not confirm the amino acid sequence, the counter-ion, or the amount of peptide by mass. Identity is normally established by a separate mass measurement.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.